To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 9077 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 9077 To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES May 29, 2026 Ms. Scholten introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Hormone Health Data and Research Act''. SEC. 2. STUDIES ON HORMONE VARIABILITY AND HORMONE TESTING WITH RESPECT TO PERIMENOPAUSE. (a) NIH Study.--The Director of the National Institutes of Health shall evaluate any evidence published on or prior to the date of enactment of this Act that relates to-- (1) the variability of hormone levels in a woman before such woman experiences symptoms of perimenopause; and (2) any baseline pattern in such variability. (b) U.S. Preventive Services Task Force Study.--The Secretary of Health and Human Services, acting through the United States Preventive Services Task Force, shall review any evidence published on or prior to the date of enactment of this Act related to the clinical utility of hormone testing, including whether baseline information obtained on the hormone levels of a woman before such woman experiences symptoms of perimenopause meaningfully informs the diagnosis or management of peri